Wednesday, July 8, 2026

pharma · Ovarian Cancer · Breast Cancer · ZNTL

Zentalis Pharmaceuticals

Zentalis Pharmaceuticals (United is a pharma organization headquartered in San Diego, USA. It trades on NYSE under ticker ZNTL. Primary therapeutic focus areas include Ovarian Cancer, Breast Cancer, High-Grade Serous Ova

10275 Science Center Dr, Suite 200, San Diego, California 92121, US HQ
123 Employees
Public company Type
ZNTL · NYSE Ticker
Company details
Status
Public
HQ
10275 Science Center Dr, Suite 200, San Diego, California 92121, US
Employees
123
Programs
14
Drugs
4
Patents
0
Clinical program

ZN-c3

Phase 1 · small molecule · Tumors

ZN-c3 for Tumors is a Phase 1 program (small_molecule) at Zentalis Pharmaceuticals with 1 ClinicalTrials.gov record(s).

← All Zentalis Pharmaceuticals projects Phase 1 small molecule terminated

Internal code 2021-0175

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Zentalis Pharmaceuticals
Phase
Phase 1
Modality
small_molecule
Indication
Tumors
Status
terminated
Trials
1

Clinical trials